MPAM
VNDA icon

Monarch Partners Asset Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Monarch Partners Asset Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-39,973
Closed -$452K – 182
2022
Q1 		$452K Hold
39,973
– – 0.1% 148
2021
Q4 		$627K Buy
+39,973
New +$697K 0.13% 151

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Monarch Partners Asset Management's VNDA Position: Q2 2022 in Review

Monarch Partners Asset Management sold out of Vanda Pharmaceuticals (VNDA) in Q2 2022, closing a stake of 39,973 shares — an estimated $452K sold.

Monarch Partners Asset Management first reported a position in VNDA in Q4 2021 and held it in 2 quarters. The position peaked at $627K in Q4 2021. 173 funds tracked by Wall St. Rank hold VNDA as of Q2 2022.

  • Monarch Partners Asset Management reported no remaining Vanda Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Monarch Partners Asset Management sold 39,973 Vanda Pharmaceuticals shares in Q2 2022, an estimated $452K.
  • Monarch Partners Asset Management first reported a position in Vanda Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Monarch Partners Asset Management's Vanda Pharmaceuticals position peaked at $627K in Q4 2021.
  • 173 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2022.

Based on Monarch Partners Asset Management's 13F filing for Q2 2022, filed 20 Jul 2022.